Table 2 Cox regression analysis of serum PCSK9 for the prediction of all-cause mortality in patients with type 2 diabetes mellitus
Predictor | Males | Males ≤ 75 yrs | Females | ||||||
|---|---|---|---|---|---|---|---|---|---|
N (%) | HR (univariable) | HR (multivariable) | N (%) | HR (univariable) | HR (multivariable) | N (%) | HR (univariable) | HR (multivariable) | |
PCSK9 ≥ 244 ng/mL | 144 (52.0) | 1.60 (1.09–2.35) | 1.25 (0.90–2.03) | 129 (51.6) | 1.99 (1.30–3.06) | 1.79 (1.13–2.82) | – | – | – |
PCSK9 ≥ 299 ng/mL | – | – | – | – | – | – | 78 (31.3) | 1.33 (0.85–2.08) | 1.08 (0.67–1.72) |
Current smoking | 41 (14.8) | – | 1.71 (1.00–2.92) | 39 (15.6) | – | 1.87 (1.07–3.27) | 37 (14.9) | – | 1.26 (0.63–2.54) |
Hypertension | 179 (64.6) | – | 1.27 (0.81–1.98) | 159 (63.6) | – | 1.24 (0.77–2.02) | 166 (66.9) | – | 1.11 (0.67–1.83) |
Statin therapy | 51 (18.4) | – | 0.64 (0.38–1.10) | 47 (18.8) | – | 0.67 (0.38–1.18) | 52 (21.0) | – | 1.31 (0.67–2.18) |
Vitamin K antagonist therapy | 28 (10.1) | – | 1.04 (0.56–1.90) | 26 (10.4) | – | 0.94 (0.48–1.83) | 24 (9.7) | – | 1.24 (0.62–2.47) |
Disease duration (years) | 277 | – | 1.01 (0.99–1.03) | 250 | – | 1.01 (1.00–1.03) | 248 | – | 1.01 (0.99–1.04) |
Age (years) | 277 | – | 1.10(1.06–1.14) | 250 | – | 1.10 (1.05–1.14) | 248 | – | 1.11 (1.07–1.16) |
HbA1c (%) | 277 | – | 1.16 (1.00–1.34) | 250 | – | 1.12 (0.95–1.32) | 248 | – | 1.18 (0.95–1.46) |
hs-CRP (mg/L) | 277 | – | 1.01 (0.98–1.04) | 250 | – | 1.00 (0.97–1.03) | 248 | – | 1.03 (1.00–1.05) |
non-HDL-C (mg/dL) | 277 | – | 1.00 (0.99–1.00) | 250 | – | 1.00 (0.99–1.01) | 248 | – | 1.00 (0.99–1.01) |
BMI (kg/m2) | 277 | – | 1.05 (1.00–1.12) | 250 | – | 1.06 (1.00–1.13) | 248 | – | 0.98 (0.94–1.03) |
eGFR (mL/min) | 277 | – | 0.99 (0.98–1.00) | 250 | – | 0.99 (0.98–1.00) | 248 | – | 0.99 (0.98–1.00) |